Company Profile

VasGene Therapeutics Inc
Profile last edited on: 11/13/2023      CAGE: 67S52      UEI:

Business Identifier: Novel therapeutics applying advances in vascular biology to treatment of cancer and eye disease.
Year Founded
1998
First Award
2012
Latest Award
2014
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1929 Zonal Avenue
Los Angeles, CA 90033
   (323) 221-7818
   info@vasgene.com
   www.vasgene.com
Location: Single
Congr. District: 34
County: Los Angeles

Public Profile

Originally organized around antitumor technologies, including angiogenesis inhibition, VasGene had been a clinical-stage company dedicated to the development and commercialization of innovative therapeutics based on the understanding of vascular biology. Breakthroughs in the basic understanding of the vascular networks combined with powerful new biotechnological tools, provided the foundation for new, rational, and technologically sophisticated approaches to cancer therapeutics. VasGene’s products target signal transduction pathways common to cancer cells and endothelial cells, resulting in powerful anti-cancer agents with multiple modes of action: inhibition of tumor cell growth, anti-angiogenesis, and prevention of tumor cell metastasis. VasGene had developed an extensive and well-protected intellectual property portfolio covering various therapeutic targets. Some time during 2018, the firm was posted as having been dissolved

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 2 NIH $1,550,654
Project Title: Sephb4-Hsa a Pre-Clinical Candidate for Oncology
2012 1 NIH $112,478
Project Title: Ephb4 Receptor Tyrosine Kinase Rtk Targeted Humanized Monoclonal Antibody H131

Key People / Management

  Parkash Gill -- Co-founder and Director

  Valery G Krasnoperov

  Raymond A Mirra Jr -- Chairman of the Board of Directors, Co-founder and Chief Executive Officer